Using the galectin-3 test to predict mortality in heart failure patients: A systematic review and meta-analysis

Biomarkers in Medicine

Volumn 10, Issue 3, 2016, Pages 329-342

  Chen, Yueh Sheng ^a   Gi, Weng Tein ^b   Liao, Tin Yun ^c   Lee, Meng Tse Gabriel ^d   Lee, Si Huei ^e   Hsu, Wan Ting ^d   Chang, Shy Shin ^a,f   Lee, Chien Chang ^d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Galectin 3; heart failure; prognostic marker

Indexed keywords

GALECTIN 3;

ACUTE HEART FAILURE; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HOSPITAL READMISSION; HUMAN; MORTALITY; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ACUTE DISEASE; CHRONIC DISEASE; HEART INFARCTION; META ANALYSIS; METABOLISM;

ACUTE DISEASE; CHRONIC DISEASE; GALECTIN 3; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION;

EID: 84959463598     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.121     Document Type: Review

References (56)

1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8(1), 30-41 (2011).
2. Mcmurray JJ, Pfeffer MA. Heart failure. Lancet 365(9474), 1877-1889 (2005).
3. De Couto G, Ouzounian M, Liu PP. Early detection of myocardial dysfunction and heart failure. Nat. Rev. Cardiol. 7(6), 334-344 (2010).
4. Mozaffarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 131(4), e29-e322 (2015).
5. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62(16), e147-e239 (2013).
6. De Lemos JA, Mcguire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 362(9380), 316-322 (2003).
7. Mcmurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14(8), 803-869 (2012).
8. Hogenhuis J, Voors AA, Jaarsma T et al. Anaemia and renal dysfunction are independently associated with BNP and NTproBNP levels in patients with heart failure. Eur. J. Heart Fail. 9(8), 787-794 (2007).
9. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J. Am. Coll. Cardiol. 47(1), 85-90 (2006).
10. Wang TJ, Larson MG, Levy D et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am. J. Cardiol. 90(3), 254-258 (2002).
11. Cooper DN. Galectinomics: finding themes in complexity. Biochim. Biophys. Acta 1572(2-3),209-231 (2002).
12. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5(1), 29-41 (2005).
13. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 128(4), 388-400 (2013).
14. De Boer RA, Voors AA, Muntendam P, Van Gilst WH, Van Veldhuisen DJ. Galectin-3: A novel mediator of heart failure development and progression. Eur. J. Heart Fail. 11(9), 811-817 (2009).
15. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur. J. Heart Fail. 15(5), 511-518 (2013).
16. Bayes-Genis A, De Antonio M, Vila J et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J. Am. Coll. Cardiol. 63(2), 158-166 (2014).
17. Carrasco-Sanchez FJ, Aramburu-Bodas O, Salamanca-Bautista P et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int. J. Cardiol. 169(3), 177-182 (2013).
18. Chang YY, Chen A, Wu XM et al. Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure. Int. J. Med. Sci. 11(11), 1098-1106 (2014).
19. Christenson RH, Duh SH, Wu AH et al. Multicenter determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin. Biochem. 43(7-8), 683-690 (2010).
20. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. Am. Heart J. 167(5), 674 e671-682 e671 (2014).
21. De Boer RA, Lok DJ, Jaarsma T et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 43(1), 60-68 (2011).
22. De Boer RA, Van Veldhuisen DJ, Gansevoort RT et al. The fibrosis marker galectin-3 and outcome in the general population. J. Intern. Med. 272(1), 55-64 (2012).
23. Felker GM, Fiuzat M, Shaw LK et al. Galectin-3 in ambulatory patients with heart failure: results from the HFACTION study. Circ. Heart Fail. 5(1), 72-78 (2012).
24. Fiuzat M, Schulte PJ, Felker M et al. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J. Card. Fail. 20(1), 38-44 (2014).
25. Gruson D, Mancini M, Ahn SA, Rousseau MF. Measurement of Galectin-3 with the ARCHITECT assay: clinical validity and cost-effectiveness in patients with heart failure. Clin. Biochem. 47(12), 1006-1009 (2014).
26. Gullestad L, Ueland T, Kjekshus J et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur. Heart J. 33(18), 2290-2296 (2012).
27. Ho JE, Liu C, Lyass A et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 60(14), 1249-1256 (2012).
28. Jungbauer CG, Riedlinger J, Block D et al. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomark. Med. 8(6), 777-789 (2014).
29. Lok DJ, Lok SI, Bruggink-Andre De La Porte PW et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin. Res. Cardiol. 102(2), 103-110 (2013).
30. Lopez-Andres N, Rossignol P, Iraqi W et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur. J. Heart Fail. 14(1), 74-81 (2012).
31. Motiwala SR, Szymonifka J, Belcher A et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur. J. Heart Fail. 15(10), 1157-1163 (2013).
32. Szadkowska I, Wlazel RN, Migala M et al. The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers 18(8), 655-659 (2013).
33. Tang WH, Shrestha K, Shao Z et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am. J. Cardiol. 108(3), 385-390 (2011).
34. Tsai TH, Sung PH, Chang LT et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J. Atheroscler. Thromb. 19(12), 1073-1082 (2012).
35. Van Kimmenade RR, Januzzi JL Jr, Ellinor PT et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 48(6), 1217-1224 (2006).
36. Jagodzinski A, Havulinna AS, Appelbaum S et al. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Int. J. Cardiol. 192, 33-39 (2015).
37. Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: A metaanalysis. Int. J. Cardiol. 182, 168-170 (2015).
38. Moher D, Shamseer L, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 4, 1 (2015).
39. Whiting PF, Rutjes AW, Westwood ME et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155(8), 529-536 (2011).
40. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J. Clin. Epidemiol. 58(10), 982-990 (2005).
41. Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol. Int. 31(7), 655-662 (2007).
42. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim. Biophys. Acta 1760(4), 616-635 (2006).
43. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172(2), 288-298 (2008).
44. Sharma UC, Pokharel S, Van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110(19), 3121-3128 (2004).
45. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101(25), 2981-2988 (2000).
46. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J. Am. Coll. Cardiol. 35(3), 569-582 (2000).
47. Califice S, Castronovo V, Van Den Brule F. Galectin-3 and cancer (review). Int. J. Oncol. 25(4), 983-992 (2004).
48. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer. Res. 6(4), 1389-1393 (2000).
49. Weigert J, Neumeier M, Wanninger J et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in Type 2 diabetes. J. Clin. Endocrinol. Metab. 95(3), 1404-1411 (2010).
50. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 132(5), 1961-1970 (1993).
51. Anand IS, Fisher LD, Chiang YT et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107(9), 1278-1283 (2003).
52. Fonarow GC, Peacock WF, Phillips CO et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J. Am. Coll. Cardiol. 49(19), 1943-1950 (2007).
53. Srivatsan V, George M, Shanmugam E. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? Eur. J. Prev. Cardiol. 22(9), 1096-1110 (2015).
54. Lok DJ, Van Der Meer P, De La Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin. Res. Cardiol. 99(5), 323-328 (2010).
55. Van Der Velde AR, Gullestad L, Ueland T et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ. Heart Fail. 6(2), 219-226 (2013).
56. Oremus M, Don-Wauchope A, Mckelvie R et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail. Rev. 19(4), 471-505 (2014).